Project Grant R21DA058713
- This federal Cooperative Agreement award, titled "Telehealth-Delivered tDCS for Cannabis Addiction Recovery: The C.A.R.E.S. (Cannabis Addiction Recovery Enhancement Stimulation) Initiative," is funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The $684,694 award supports the development and testing of a novel, home-based intervention that combines transcranial direct current stimulation (tDCS) with mindfulness...
- This is a Cooperative Agreement awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant provides $1,360,200 to the Regents of the University of Minnesota, doing business as the Office of Sponsored Projects Administration, to conduct a research project titled "COMBINED TDCS AND COGNITIVE TRAINING AS AN ADJUNCTIVE TREATMENT IN OPIOID USE DISORDER." The research...
- This federal Project Grant award of $686,692 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports a study to assess the potential benefits of reduced cannabis consumption for adults with cannabis use disorder (CUD). The study will conduct an 8-week cannabis use reduction trial, where participants receive comprehensive CUD treatment including cognitive behavioral therapy, motivational interviewing, and incentives for...
- This $668,110 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund the development and acceptability testing of a technology-based intervention to reduce cannabis misuse among college students. The project aims to refine an existing intervention that provides information on cannabis products, marketing, laws, and risks to increase young adults' cannabis literacy. The research will involve focus groups with...
- The National Institute on Drug Abuse (NIDA) awarded a $1,585,991 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Icahn School of Medicine at Mount Sinai (ISMMS) on May 1, 2025. The grant will fund a double-blind randomized clinical trial to evaluate the efficacy of combining transcranial direct current stimulation (tDCS) over the dorsolateral prefrontal cortex with cognitive reappraisal training to reduce craving and cue-reactivity in individuals with...
- The National Institute on Drug Abuse (NIDA) awarded a $357,806 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Trustees of Indiana University in Indianapolis. The grant will fund a research study to investigate the neural activity underlying instrumental learning and its relationship to treatment outcomes for adolescent cannabis use disorder (CUD). Specifically, the study aims to: (1) identify associations between CUD symptomatology and neural activity during...
- This $197,640 Project Grant, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports the development and pilot testing of a digital therapeutic called AMP-C. AMP-C targets reward dysfunction in individuals with co-occurring cannabis use disorder and major depressive disorder. The 5-year project, led by Dr. Collins at The General Hospital Corporation (doing business as Massachusetts General Hospital), aims to evaluate the...
- This federal Project Grant award, valued at $420,519.00 and provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports a clinical trial to evaluate the use of non-invasive Temporal Interference (TI) electrical neurostimulation to reduce nicotine craving and use in heavy smokers and vape users. The project, which runs from July 15, 2025 to June 30, 2027, aims to test the effects of 60-minute TI stimulation targeting the...
- This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $450,313 to evaluate the impact of psychotherapeutic advertising claims on cannabis purchasing behaviors among individuals with symptoms of depression and/or anxiety. The project aims to investigate the influence of psychotherapeutic advertising claims and mental health warning labels on online cannabis purchasing by simulating a...
- This federal Project Grant award of $551,464.00 was provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) to the Palo Alto Veterans Institute for Research (Pavir) to evaluate the efficacy of deep transcranial magnetic stimulation (DTMS) in reducing alcohol use disorder (AUD) symptoms. The key objectives of this 5-year project are to: 1) evaluate if active DTMS increases activation of the dorsal anterior cingulate cortex...
EXAMINATION OF POTENTIAL EFFECTIVENESS OF TRANSCRANIAL DIRECT CURRENT STIMULATION (TDCS) PAIRED WITH REAPPRAISAL TRAINING FOR CANNABIS USE DISORDER - PROJECT ABSTRACT AS CANNABIS BECOMES LEGALIZED IN REGIONS AROUND THE COUNTRY, DEVELOPING EFFECTIVE TREATMENTS FOR CANNABIS USE DISORDER (CUD) BECOMES INCREASINGLY IMPORTANT. TRANSCRANIAL DIRECT CURRENT STIMULATION (TDCS) HOLDS PROMISE AS AN AUGMENT TO EXISTING BEHAVIORAL TREATMENTS. BASED ON RECENT WORK IN INTERNET GAMING DISORDER BY OUR TEAM, ENHANCEMENT OF REGULATION SKILLS THROUGH TDCS OF THE DORSO-LATERAL PREFRONTAL CORTEX (DLPFC) MAY CONSTITUTE A HELPFUL TREATMENT FOR ADDICTIVE BEHAVIORS. PAIRING TDCS OF THE DLPFC WITH SPECIFIC TRAINING IN REAPPRAISAL MAY FURTHER HELP INDIVIDUALS REGULATE CRAVING BY ENHANCING EFFECTIVENESS OF TRAINING IN THE BENEFICIAL EMOTIONAL REGULATION STRATEGY OF REAPPRAISAL. THUS, THE GOAL OF THIS WORK IS TO EXAMINE IF NEUROSTIMULATION PAIRED WITH REAPPRAISAL TRAINING MAY ENHANCE EMOTIONAL REGULATION, RESULTING IN A REDUCTION OF CANNABIS USE COUPLED WITH CHANGE IN EEG CORRELATES OF REGULATION. SIXTY PARTICIPANTS WILL BE RECRUITED AND ASSIGNED TO EITHER RECEIVE REAL OR SHAM TDCS ALONGSIDE REAPPRAISAL TRAINING IN 5 WEEKLY SINGLE 20-MINUTE SESSIONS USING A DOUBLE-BLIND DESIGN. CANNABIS USE WILL BE MEASURED DAILY USING ECOLOGICAL MOMENTARY ASSESSMENT (EMA) FOR THE DURATION OF THE MONTH. USE OF EMA TECHNIQUE WILL ALLOW US TO OBTAIN DETAILED CANNABIS USE INFORMATION AND DETERMINE ANY CHANGE IN USE PATTERNS. FURTHER, WE WILL EXAMINE EEG CORRELATES OF REGULATION OF CRAVING, USING THE REGULATION OF CRAVING TASK, AFTER TDCS AT THE FIRST AND FINAL VISIT. USE OF EEG DURING THE REGULATION OF CRAVING TASK POST-STIMULATION AT BASELINE AND POST-TREATMENT WILL ALLOW US TO DETERMINE IF DLPFC STIMULATION RESULTS IN ENHANCEMENT OF REAPPRAISAL COUPLED WITH BOTH REDUCTION IN SELF-REPORT OF CRAVING TO CANNABIS IMAGES AND CHANGES IN EEG CORRELATES OF REGULATORY CONTROL AND REACTIVITY WHILE PARTICIPANTS ATTEMPT TO REGULATE THEIR CRAVING. WE PREDICT THAT REAL, AS OPPOSED TO SHAM, TDCS WILL BE ASSOCIATED WITH REDUCTION IN CANNABIS USE AS MEASURED BY EMA, ALONG WITH REDUCTIONS IN SELF-REPORTED CRAVING AND ENHANCEMENT OF EEG CORRELATES OF REGULATION AT THE FINAL VISIT. IF OUR PREDICTIONS HOLD, FINDINGS WILL SERVE AS IMPORTANT PROOF-OF-CONCEPT DATA ON THE EFFECTIVENESS OF TDCS IN TANDEM WITH REAPPRAISAL TRAINING AS A POTENTIAL TREATMENT AUGMENT FOR CUD AS WELL AS ELUCIDATING POTENTIAL MECHANISMS BY WHICH TDCS WORKS. THESE DATA WILL SET THE STAGE FOR FUTURE WORK IN LARGER SAMPLES AND LONGER DURATIONS INVESTIGATING TDCS AS A METHOD TO AUGMENT TREATMENT FOR CUD.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $209.4k | 6/23/25 | ||
| Not listed | $247.9k | 6/21/24 |